Lercanidipino Mabo (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in the smooth muscle of arterial walls. This inhibition prevents calcium‑mediated contraction, causing the vessels to relax and dilate. The resulting decrease in peripheral vascular resistance leads to lower systemic blood pressure.

The appropriate dose of Lercanidipino Mabo is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any comorbidities. Dosage adjustments are made according to individual therapeutic needs.

Safety of lercanidipine during pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both lercanidipine and amlodipine are dihydropyridine calcium channel blockers that lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may provide smoother blood‑pressure control with a lower incidence of reflex tachycardia, while amlodipine is more widely used and has an extensive safety record.

Store Lercanidipino Mabo at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat, and direct sunlight to maintain stability and potency.

Lercanidipino Mabo is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious adverse events, though rare, include severe hypotension, angio‑edema, and hepatic dysfunction. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the face or throat, or signs of liver injury such as jaundice.

Lercanidipino Mabo is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis or uncontrolled heart failure unless specifically advised by a physician.